{"altmetric_id":21219792,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["InDex Pharmaceuticals"],"first_seen_on":"2017-06-21T12:25:04+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1498062361,"links":["http:\/\/www.clinicaltrials.gov\/show\/NCT03178669"],"nct_id":"NCT03178669","pubdate":"2017-06-05T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"The Efficacy of Cobitolimod in Patients With Moderate to Severe, Active Ulcerative Colitis (CONDUCT)","type":"clinical_trial_study_record"},"altmetric_score":{"score":43,"score_history":{"1y":43,"6m":43,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":43},"context_for_score":{"all":{"total_number_of_other_articles":8403724,"mean":7.0757025513494,"rank":218774,"this_scored_higher_than_pct":97,"this_scored_higher_than":8184581,"rank_type":"exact","sample_size":8403724,"percentile":97},"similar_age_3m":{"total_number_of_other_articles":237167,"mean":12.930647706669,"rank":13296,"this_scored_higher_than_pct":94,"this_scored_higher_than":223848,"rank_type":"exact","sample_size":237167,"percentile":94},"this_journal":{"total_number_of_other_articles":24736,"mean":10.525193127148,"rank":741,"this_scored_higher_than_pct":96,"this_scored_higher_than":23987,"rank_type":"exact","sample_size":24736,"percentile":96},"similar_age_this_journal_3m":{"total_number_of_other_articles":908,"mean":7.6354134509372,"rank":21,"this_scored_higher_than_pct":97,"this_scored_higher_than":887,"rank_type":"exact","sample_size":908,"percentile":97}}},"demographics":[],"counts":{"total":{"posts_count":6},"news":{"unique_users_count":6,"unique_users":["nasdaq","ticker_tech","bioportfolio","biospace","2_news","biotech_gate"],"posts_count":6}},"posts":{"news":[{"title":"InDex Pharmaceuticals Enrolls First Patient in the Phase IIb Study CONDUCT With Cobitolimod","url":"http:\/\/ct.moreover.com\/?a=30970098224&p=1pl&v=1&x=kobT_9g9rrV0uKe8UkwMfA","license":"public","citation_ids":[21219792],"posted_on":"2017-06-21T12:11:00+00:00","summary":"\/PRNewswire\/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical study CONDUCT - a phase IIb dose optimisation study with the drug candidate cobitolimod.","author":{"name":"NASDAQ","url":"http:\/\/www.nasdaq.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/839\/normal\/Screen_Shot_2016-01-27_at_11.14.52.png?1453893369"}},{"title":"InDex Pharmaceuticals Enrolls First Patient in the Phase IIb Study CONDUCT With Cobitolimod","url":"http:\/\/ct.moreover.com\/?a=30970114619&p=1pl&v=1&x=MfZE8jLd9XLpby8ucsEoeA","license":"public","citation_ids":[21219792],"posted_on":"2017-06-21T12:17:44+00:00","summary":"\/PRNewswire\/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical study CONDUCT \u2013 a phase IIb dose optimisation study with the drug candidate cobitolimod.","author":{"name":"Ticker Tech","url":"http:\/\/www.tickertech.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/724\/normal\/Screen_Shot_2016-01-26_at_15.37.40.png?1453822700"}},{"title":"InDex Pharmaceuticals Enrolls First Patient in the Phase IIb Study CONDUCT With Cobitolimod","url":"http:\/\/ct.moreover.com\/?a=30970390752&p=1pl&v=1&x=ZGhqkGA7iN796O4uFw_xmA","license":"public","citation_ids":[21219792],"posted_on":"2017-06-21T08:33:12+00:00","summary":"STOCKHOLM, June 21, 2017 \/PRNewswire\/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical study CONDUCT \u2013 a phase IIb dose optimisation study with the drug candidate cobitolimod.","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"InDex Pharmaceuticals AB Enrolls First Patient In The Phase IIb Study CONDUCT With Cobitolimod","url":"http:\/\/ct.moreover.com\/?a=30970426424&p=1pl&v=1&x=3zQ-ntOHAK7NCvT73f-Nhw","license":"public","citation_ids":[21219792],"posted_on":"2017-06-21T00:00:00+00:00","summary":"\/PRNewswire\/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical study CONDUCT a phase IIb dose optimisation study with the drug candidate cobitolimod.","author":{"name":"Biospace","url":"http:\/\/www.biospace.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/375\/normal\/biospace.png?1437140433"}},{"title":"InDex Pharmaceuticals Enrolls First Patient in the Phase IIb Study CONDUCT With Cobitolimod","url":"http:\/\/ct.moreover.com\/?a=30970436413&p=1pl&v=1&x=W0kSmlSdgUpvyrE7MGHwUA","license":"public","citation_ids":[21219792],"posted_on":"2017-06-21T12:52:33+00:00","summary":"Information contained on this page is provided by an independent third-party content provider.","author":{"name":"2 News","url":"http:\/\/www.ktvn.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/654\/normal\/Screen_Shot_2016-01-26_at_12.05.19.png?1453809947"}},{"title":"InDex Pharmaceuticals Enrolls First Patient in the Phase IIb Study CONDUCT With Cobitolimod","url":"http:\/\/ct.moreover.com\/?a=30972558865&p=1pl&v=1&x=yymlR4U7OHMmcxw1F94aFg","license":"public","citation_ids":[21219792],"posted_on":"2017-06-21T16:26:01+00:00","summary":"\/PRNewswire\/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical study CONDUCT \u2013 a phase IIb dose optimisation study with the drug candidate cobitolimod.","author":{"name":"BioTech Gate","url":"http:\/\/www.biotechgate.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/835\/normal\/Screen_Shot_2016-01-27_at_11.07.21.png?1453892866"}}]}}